NICE recommends first targeted treatment for MZL
The first targeted treatment zanubrutinib, is now available for people with marginal zone lymphoma
Read the latest news and views from Lymphoma Action.
Use the drop down filter to find the most relevant news for you.
The first targeted treatment zanubrutinib, is now available for people with marginal zone lymphoma
Treatment recommended for patients with relapsed or refractory DLBCL who have had at least two other lines of treatment.
New treatment available for relapsed or refractory classical Hodgkin lymphoma.
The Scottish Medicines Consortium recommends loncastuximab tesirine but not axicabtagene ciloleucel as treatment for diffuse large B-cell lymphoma and high-grade B-cell lymphoma.
New third line treatment available for relapsed or refractory diffuse large B-cell lymphoma.
New treatment available for relapsed or refractory diffuse large B-cell lymphoma.
A summary of our submission to the National Institute for Health Care and Excellence (NICE) for Evusheld.
Evusheld, the COVID-19 treatment which could prevent disease.
Venetoclax has been recommended for adults with chronic lymphocytic leukaemia.
NICE is not recommending ibrutinib for treating Waldenström’s macroglobulinaemia in adults who have had at least one previous treatment.